Current List of Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies, 7795-7797 [2013-02310]

Download as PDF Federal Register / Vol. 78, No. 23 / Monday, February 4, 2013 / Notices (Catalogue of Federal Domestic Assistance Program Nos. 93.115, Biometry and Risk Estimation—Health Risks from Environmental Exposures; 93.142, NIEHS Hazardous Waste Worker Health and Safety Training; 93.143, NIEHS Superfund Hazardous Substances—Basic Research and Education; 93.894, Resources and Manpower Development in the Environmental Health Sciences; 93.113, Biological Response to Environmental Health Hazards; 93.114, Applied Toxicological Research and Testing, National Institutes of Health, HHS) Dated: January 29, 2013. Carolyn Baum, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2013–02271 Filed 2–1–13; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Heart, Lung, and Blood Institute; Notice of Closed Meeting mstockstill on DSK4VPTVN1PROD with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; Review of a resource grant application in rat embryonic stem cell lines. Date: February 21, 2013. Time: 1:00 p.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Room 7206, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Shelley S Sehnert, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7206, Bethesda, MD 20892–7924, 301–435– 0303, ssehnert@nhlbi.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS) VerDate Mar<15>2010 19:26 Feb 01, 2013 Jkt 229001 Dated: January 29, 2013. Michelle Trout, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2013–02277 Filed 2–1–13; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Fogarty International Center; Notice of Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the Fogarty International Center Advisory Board. The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract Proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable materials, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Fogarty International Center Advisory Board. Date: February 25–26, 2013. Closed: February 25, 2013, 2:00 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications and/or proposals. Place: National Institutes of Health, Building 31, 31 Center Drive, C Wing, Room B2C03, Bethesda, MD 20892. Open: February 26, 2013 9:00 a.m. to 3:00 p.m. Agenda: Discussions will focus on new directions for Fogarty International Center non-communicable diseases portfolio and strengthening collaborations between researchers and implementers and policymakers. Place: National Institutes of Health, Lawton L. Chiles International House, Bethesda, MD 20892. Contact Person: Robert Eiss, Public Health Advisor, Fogarty International Center, National Institutes of Health, 31 Center Drive, Room B2c02, Bethesda, MD 20892, (301) 496–1415, EISSR@MAIL.NIH.GOV. PO 00000 Frm 00058 Fmt 4703 Sfmt 4703 7795 Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver’s license, or passport) and to state the purpose of their visit. Information is also available on the Institute’s/Center’s home page: www.nih.gov/ fic/about/advisory.html, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.106, Minority International Research Training Grant in the Biomedical and Behavioral Sciences; 93.154, Special International Postdoctoral Research Program in Acquired Immunodeficiency Syndrome; 93.168, International Cooperative Biodiversity Groups Program; 93.934, Fogarty International Research Collaboration Award; 93.989, Senior International Fellowship Awards Program, National Institutes of Health HHS) Dated: January 29, 2013. Michelle Trout, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2013–02282 Filed 2–1–13; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Current List of Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies Substance Abuse and Mental Health Services Administration, HHS. ACTION: Notice. AGENCY: The Department of Health and Human Services (HHS) notifies Federal agencies of the Laboratories and Instrumented Initial Testing Facilities (IITF) currently certified to meet the standards of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory Guidelines were first published in the Federal Register on April 11, 1988 (53 FR 11970), and subsequently revised in the Federal Register on June 9, 1994 (59 FR 29908); September 30, 1997 (62 FR 51118); SUMMARY: E:\FR\FM\04FEN1.SGM 04FEN1 7796 Federal Register / Vol. 78, No. 23 / Monday, February 4, 2013 / Notices April 13, 2004 (69 FR 19644); November 25, 2008 (73 FR 71858); December 10, 2008 (73 FR 75122); and on April 30, 2010 (75 FR 22809). A notice listing all currently certified Laboratories and Instrumented Initial Testing Facilities (IITF) is published in the Federal Register during the first week of each month. If any Laboratory/ IITF’s certification is suspended or revoked, the Laboratory/IITF will be omitted from subsequent lists until such time as it is restored to full certification under the Mandatory Guidelines. If any Laboratory/IITF has withdrawn from the HHS National Laboratory Certification Program (NLCP) during the past month, it will be listed at the end and will be omitted from the monthly listing thereafter. This notice is also available on the Internet at https:// www.workplace.samhsa.gov and https:// www.drugfreeworkplace.gov. Mrs. Giselle Hersh, Division of Workplace Programs, SAMHSA/CSAP, Room 2– 1042, One Choke Cherry Road, Rockville, Maryland 20857; 240–276– 2600 (voice), 240–276–2610 (fax). SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were initially developed in accordance with Executive Order 12564 and section 503 of Public Law 100–71. The ‘‘Mandatory Guidelines for Federal Workplace Drug Testing Programs’’, as amended in the revisions listed above, requires strict standards that Laboratories and Instrumented Initial Testing Facilities (IITF) must meet in order to conduct drug and specimen validity tests on urine specimens for Federal agencies. To become certified, an applicant Laboratory/IITF must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification, a Laboratory/IITF must participate in a quarterly performance testing program plus undergo periodic, on-site inspections. Laboratories and Instrumented Initial Testing Facilities (IITF) in the applicant stage of certification are not to be considered as meeting the minimum requirements described in the HHS Mandatory Guidelines. A Laboratory/ IITF must have its letter of certification from HHS/SAMHSA (formerly: HHS/ NIDA) which attests that it has met minimum standards. In accordance with the Mandatory Guidelines dated November 25, 2008 (73 FR 71858), the following Laboratories and Instrumented Initial Testing Facilities (IITF) meet the minimum standards to conduct drug mstockstill on DSK4VPTVN1PROD with NOTICES FOR FURTHER INFORMATION CONTACT: VerDate Mar<15>2010 19:26 Feb 01, 2013 Jkt 229001 and specimen validity tests on urine specimens: Instrumented Initial Testing Facilities (IITF) None. Laboratories ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227, 414–328– 7840/800–877–7016, (Formerly: Bayshore Clinical Laboratory) ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 14624, 585–429–2264 Advanced Toxicology Network, 3560 Air Center Cove, Suite 101, Memphis, TN 38118, 901–794–5770/888–290– 1150 Aegis Analytical Laboratories, 345 Hill Ave., Nashville, TN 37210, 615–255– 2400, (Formerly: Aegis Sciences Corporation, Aegis Analytical Laboratories, Inc.) Alere Toxicology Services, 1111 Newton St., Gretna, LA 70053, 504–361–8989/ 800–433–3823, (Formerly: Kroll Laboratory Specialists, Inc., Laboratory Specialists, Inc.) Alere Toxicology Services, 450 Southlake Blvd., Richmond, VA 23236, 804–378–9130, (Formerly: Kroll Laboratory Specialists, Inc., Scientific Testing Laboratories, Inc.; Kroll Scientific Testing Laboratories, Inc.) Baptist Medical Center-Toxicology Laboratory, 11401 I–30, Little Rock, AR 72209–7056, 501–202–2783, (Formerly: Forensic Toxicology Laboratory Baptist Medical Center) Clinical Reference Lab, 8433 Quivira Road, Lenexa, KS 66215–2802, 800– 445–6917 Doctors Laboratory, Inc., 2906 Julia Drive, Valdosta, GA 31602, 229–671– 2281 DrugScan, Inc., 200 Precision Road, Suite 200, Horsham, PA 19044, 800– 235–4890 ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS 38655, 662– 236–2609 Fortes Laboratories, Inc., 25749 SW. Canyon Creek Road, Suite 600, Wilsonville, OR 97070, 503–486–1023 Gamma-Dynacare Medical Laboratories*, A Division of the Gamma-Dynacare Laboratory Partnership, 245 Pall Mall Street, London, ONT, Canada N6A 1P4, 519– 679–1630 Laboratory Corporation of America Holdings, 7207 N. Gessner Road, Houston, TX 77040, 713–856–8288/ 800–800–2387 Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ 08869, 908–526–2400/800–437–4986, PO 00000 Frm 00059 Fmt 4703 Sfmt 4703 (Formerly: Roche Biomedical Laboratories, Inc.) Laboratory Corporation of America Holdings, 1904 Alexander Drive, Research Triangle Park, NC 27709, 919– 572–6900/800–833–3984, (Formerly: LabCorp Occupational Testing Services, Inc., CompuChem Laboratories, Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche Group) Laboratory Corporation of America Holdings, 1120 Main Street, Southaven, MS 38671, 866–827–8042/800–233– 6339, (Formerly: LabCorp Occupational Testing Services, Inc.; MedExpress/ National Laboratory Center) LabOne, Inc. d/b/a Quest Diagnostics, 10101 Renner Blvd., Lenexa, KS 66219, 913–888–3927/800–873–8845, (Formerly: Quest Diagnostics Incorporated; LabOne, Inc.; Center for Laboratory Services, a Division of LabOne, Inc.,) MedTox Laboratories, Inc., 402 W. County Road D, St. Paul, MN 55112, 651–636–7466/800–832–3244 MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR 97232, 503–413–5295/800–950–5295 Minneapolis Veterans Affairs Medical Center, Forensic Toxicology Laboratory, 1 Veterans Drive, Minneapolis, MN 55417, 612–725–2088 National Toxicology Laboratories, Inc., 1100 California Ave., Bakersfield, CA 93304, 661–322–4250/800–350– 3515 One Source Toxicology Laboratory, Inc., 1213 Genoa-Red Bluff, Pasadena, TX 77504, 888–747–3774, (Formerly: University of Texas Medical Branch, Clinical Chemistry Division; UTMB Pathology-Toxicology Laboratory) Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA 91311, 800–328–6942, (Formerly: Centinela Hospital Airport Toxicology Laboratory) Pathology Associates Medical Laboratories, 110 West Cliff Dr., Spokane, WA 99204, 509–755–8991/ 800–541–7891x7 Phamatech, Inc., 10151 Barnes Canyon Road, San Diego, CA 92121, 858–643–5555 Quest Diagnostics Incorporated, 1777 Montreal Circle, Tucker, GA 30084, 800–729–6432, (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-Science Laboratories) Quest Diagnostics Incorporated, 400 Egypt Road, Norristown, PA 19403, 610–631–4600/877–642–2216, (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline BioScience Laboratories) E:\FR\FM\04FEN1.SGM 04FEN1 mstockstill on DSK4VPTVN1PROD with NOTICES Federal Register / Vol. 78, No. 23 / Monday, February 4, 2013 / Notices Quest Diagnostics Incorporated, 8401 Fallbrook Ave., West Hills, CA 91304, 818–737–6370, (Formerly: SmithKline Beecham Clinical Laboratories) Redwood Toxicology Laboratory, 3650 Westwind Blvd., Santa Rosa, CA 95403, 707–570–4434 South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South Bend, IN 46601, 574–234–4176 x1276 Southwest Laboratories, 4625 E. Cotton Center Boulevard, Suite 177, Phoenix, AZ 85040, 602–438–8507/800–279– 0027 STERLING Reference Laboratories, 2617 East L Street, Tacoma, Washington 98421, 800–442–0438 Toxicology & Drug Monitoring Laboratory, University of Missouri Hospital & Clinics, 301 Business Loop 70 West, Suite 208, Columbia, MO 65203, 573–882–1273 U.S. Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson St., Fort George G. Meade, MD 20755– 5235, 301–677–7085 *The Standards Council of Canada (SCC) voted to end its Laboratory Accreditation Program for Substance Abuse (LAPSA) effective May 12, 1998. Laboratories certified through that program were accredited to conduct forensic urine drug testing as required by U.S. Department of Transportation (DOT) regulations. As of that date, the certification of those accredited Canadian laboratories will continue under DOT authority. The responsibility for conducting quarterly performance testing plus periodic on-site inspections of those LAPSA-accredited laboratories was transferred to the U.S. HHS, with the HHS’ NLCP contractor continuing to have an active role in the performance testing and laboratory inspection processes. Other Canadian laboratories wishing to be considered for the NLCP may apply directly to the NLCP contractor just as U.S. laboratories do. Upon finding a Canadian laboratory to be qualified, HHS will recommend that DOT certify the laboratory (Federal Register, July 16, 1996) as meeting the minimum standards of the Mandatory Guidelines published in the Federal Register on April 30, 2010 (75 FR 22809). After receiving DOT certification, the laboratory will be included in the monthly list of HHScertified laboratories and participate in the NLCP certification maintenance program. Janine Denis Cook, Chemist, Division of Workplace Programs, Center for Substance Abuse Prevention, SAMHSA. [FR Doc. 2013–02310 Filed 2–1–13; 8:45 am] BILLING CODE 4160–20–P VerDate Mar<15>2010 19:26 Feb 01, 2013 Jkt 229001 DEPARTMENT OF HOMELAND SECURITY [Docket No. DHS–2013–0005] Homeland Security Information Network Advisory Committee (HSINAC) OPS/OCIO, DHS. Committee Management; Notice of Federal Advisory Committee Meeting. AGENCY: ACTION: The Homeland Security Information Network Advisory Committee (HSIN AC) will meet on February 27th–28th, 2013 in Washington, DC. The meeting will be open to the public. DATES: HSIN AC will meet Wednesday, February 27th, 2013 from 9 a.m. to 5 p.m. and on Thursday, February 28th, 2013 from 9 a.m. to 2 p.m. Please note that the meeting may end early if the committee has completed its business. ADDRESSES: The meeting will be held at the Ronald Reagan International Trade Center (Ronald Reagan Building), 1300 Pennsylvania Ave. NW., Washington DC 20004. All visitors to the Ronald Reagan International Trade Center are required to show government identification for admittance to the building. In the event of inclement weather affecting the Washington, DC area, creating a delay in the opening of Federal offices, the contingency plan will be to hold the conference via a teleconference call and if possible Adobe Connect session, requesting that all participants and visitors participate virtually. If the Federal government is closed, the meeting will be rescheduled. Please provide your name, telephone number and email by close of business on February 25th, 2013, to the contact person listed in FOR FURTHER INFORMATION CONTACT below. Teleconference lines will be available for this meeting. For information on facilities or services for individuals with disabilities or to request special assistance at the meeting, contact David Steigman, david.steigman@hq.dhs.gov, 202–357– 7809, as soon as possible. To facilitate public participation, we are inviting public comment on the issues to be considered by the committee as listed in the ‘‘Agenda’’ section below. Comments must be submitted in writing no later than February 20, 2013 and must be identified by docket number: DHS– 2013–0005 and may be submitted by one of the following methods: • Federal eRulemaking Portal: https:// www.regulations.gov. Follow the instructions for submitting comments. SUMMARY: PO 00000 Frm 00060 Fmt 4703 Sfmt 4703 7797 • Email: David Steigman, david.steigman@hq.dhs.gov. Include the docket number in the subject line of the message. • Fax: 202–357–7678. • Mail: David Steigman, Department of Homeland Security, OPS CIO–D Stop 0426, 245 Murray Lane, SW., BLDG 410, Washington, DC 20528–0426. Instructions: All submissions received must include the words ‘‘Department of Homeland Security’’ and the docket number for this action. Comments received will be posted without alteration at https://www.regulations.gov, including any personal information provided. Docket: For access to the docket to read background documents or comments received by the (Homeland Security Information Network Advisory Committee), go to https:// www.regulations.gov. Short public comment periods will be held during the meeting following presentations. Those providing comments are requested to limit their comments to 3 minutes. Please note that the public comment period may end before the time indicated, following the last call for comments. Contact the individual listed below to register as a speaker. Documents will be distributed to the committee members during the meeting and made available to the public on February 27, 2013 on the Federal Register Web site at: https:// www.federalregister.gov/agencies/ homeland-security-department. These documents will be formatted in the Microsoft Suite software applications. FOR FURTHER INFORMATION CONTACT: Designated Federal Officer, David Steigman, david.steigman@hq.dhs.gov, Phone: 202–357–7809, Fax: 202–357– 7678, or Alternate Designated Federal Officer, Sarah Schwettman, sarah.schwettman@hq.dhs.gov, Phone: 202–357–7882. SUPPLEMENTARY INFORMATION: Notice of this meeting is given under the Federal Advisory Committee Act, 5 U.S.C. App. (Pub. L. 92–463). The HSINAC provides advice and recommendations to the U.S. Department of Homeland Security (DHS) on matters relating to HSIN. These matters include system requirements, operating policies, community organization, knowledge management, interoperability and federation with other systems, and any other aspect of HSIN that supports the operations of DHS and its Federal, State, territorial, local, tribal, international, and private sector mission partners. The HSINAC provides independent advice and recommendations to the leadership E:\FR\FM\04FEN1.SGM 04FEN1

Agencies

[Federal Register Volume 78, Number 23 (Monday, February 4, 2013)]
[Notices]
[Pages 7795-7797]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-02310]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration


Current List of Laboratories and Instrumented Initial Testing 
Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing 
for Federal Agencies

AGENCY: Substance Abuse and Mental Health Services Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Department of Health and Human Services (HHS) notifies 
Federal agencies of the Laboratories and Instrumented Initial Testing 
Facilities (IITF) currently certified to meet the standards of the 
Mandatory Guidelines for Federal Workplace Drug Testing Programs 
(Mandatory Guidelines). The Mandatory Guidelines were first published 
in the Federal Register on April 11, 1988 (53 FR 11970), and 
subsequently revised in the Federal Register on June 9, 1994 (59 FR 
29908); September 30, 1997 (62 FR 51118);

[[Page 7796]]

April 13, 2004 (69 FR 19644); November 25, 2008 (73 FR 71858); December 
10, 2008 (73 FR 75122); and on April 30, 2010 (75 FR 22809).
    A notice listing all currently certified Laboratories and 
Instrumented Initial Testing Facilities (IITF) is published in the 
Federal Register during the first week of each month. If any 
Laboratory/IITF's certification is suspended or revoked, the 
Laboratory/IITF will be omitted from subsequent lists until such time 
as it is restored to full certification under the Mandatory Guidelines.
    If any Laboratory/IITF has withdrawn from the HHS National 
Laboratory Certification Program (NLCP) during the past month, it will 
be listed at the end and will be omitted from the monthly listing 
thereafter.
    This notice is also available on the Internet at https://www.workplace.samhsa.gov and https://www.drugfreeworkplace.gov.

FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh, Division of 
Workplace Programs, SAMHSA/CSAP, Room 2-1042, One Choke Cherry Road, 
Rockville, Maryland 20857; 240-276-2600 (voice), 240-276-2610 (fax).

SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were initially 
developed in accordance with Executive Order 12564 and section 503 of 
Public Law 100-71. The ``Mandatory Guidelines for Federal Workplace 
Drug Testing Programs'', as amended in the revisions listed above, 
requires strict standards that Laboratories and Instrumented Initial 
Testing Facilities (IITF) must meet in order to conduct drug and 
specimen validity tests on urine specimens for Federal agencies.
    To become certified, an applicant Laboratory/IITF must undergo 
three rounds of performance testing plus an on-site inspection. To 
maintain that certification, a Laboratory/IITF must participate in a 
quarterly performance testing program plus undergo periodic, on-site 
inspections.
    Laboratories and Instrumented Initial Testing Facilities (IITF) in 
the applicant stage of certification are not to be considered as 
meeting the minimum requirements described in the HHS Mandatory 
Guidelines. A Laboratory/IITF must have its letter of certification 
from HHS/SAMHSA (formerly: HHS/NIDA) which attests that it has met 
minimum standards.
    In accordance with the Mandatory Guidelines dated November 25, 2008 
(73 FR 71858), the following Laboratories and Instrumented Initial 
Testing Facilities (IITF) meet the minimum standards to conduct drug 
and specimen validity tests on urine specimens:

Instrumented Initial Testing Facilities (IITF)

    None.

Laboratories

ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227, 414-328-
7840/800-877-7016, (Formerly: Bayshore Clinical Laboratory)
ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 14624, 
585-429-2264
Advanced Toxicology Network, 3560 Air Center Cove, Suite 101, Memphis, 
TN 38118, 901-794-5770/888-290-1150
Aegis Analytical Laboratories, 345 Hill Ave., Nashville, TN 37210, 615-
255-2400, (Formerly: Aegis Sciences Corporation, Aegis Analytical 
Laboratories, Inc.)
Alere Toxicology Services, 1111 Newton St., Gretna, LA 70053, 504-361-
8989/800-433-3823, (Formerly: Kroll Laboratory Specialists, Inc., 
Laboratory Specialists, Inc.)
Alere Toxicology Services, 450 Southlake Blvd., Richmond, VA 23236, 
804-378-9130, (Formerly: Kroll Laboratory Specialists, Inc., Scientific 
Testing Laboratories, Inc.; Kroll Scientific Testing Laboratories, 
Inc.)
Baptist Medical Center-Toxicology Laboratory, 11401 I-30, Little Rock, 
AR 72209-7056, 501-202-2783, (Formerly: Forensic Toxicology Laboratory 
Baptist Medical Center)
Clinical Reference Lab, 8433 Quivira Road, Lenexa, KS 66215-2802, 800-
445-6917
Doctors Laboratory, Inc., 2906 Julia Drive, Valdosta, GA 31602, 229-
671-2281
DrugScan, Inc., 200 Precision Road, Suite 200, Horsham, PA 19044, 800-
235-4890
ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS 38655, 
662-236-2609
Fortes Laboratories, Inc., 25749 SW. Canyon Creek Road, Suite 600, 
Wilsonville, OR 97070, 503-486-1023
Gamma-Dynacare Medical Laboratories*, A Division of the Gamma-Dynacare 
Laboratory Partnership, 245 Pall Mall Street, London, ONT, Canada N6A 
1P4, 519-679-1630
Laboratory Corporation of America Holdings, 7207 N. Gessner Road, 
Houston, TX 77040, 713-856-8288/800-800-2387
Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ 
08869, 908-526-2400/800-437-4986, (Formerly: Roche Biomedical 
Laboratories, Inc.)
    Laboratory Corporation of America Holdings, 1904 Alexander Drive, 
Research Triangle Park, NC 27709, 919-572-6900/800-833-3984, (Formerly: 
LabCorp Occupational Testing Services, Inc., CompuChem Laboratories, 
Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical 
Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche 
Group)
    Laboratory Corporation of America Holdings, 1120 Main Street, 
Southaven, MS 38671, 866-827-8042/800-233-6339, (Formerly: LabCorp 
Occupational Testing Services, Inc.; MedExpress/National Laboratory 
Center)
    LabOne, Inc. d/b/a Quest Diagnostics, 10101 Renner Blvd., Lenexa, 
KS 66219, 913-888-3927/800-873-8845, (Formerly: Quest Diagnostics 
Incorporated; LabOne, Inc.; Center for Laboratory Services, a Division 
of LabOne, Inc.,)
    MedTox Laboratories, Inc., 402 W. County Road D, St. Paul, MN 
55112, 651-636-7466/800-832-3244
    MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR 
97232, 503-413-5295/800-950-5295
    Minneapolis Veterans Affairs Medical Center, Forensic Toxicology 
Laboratory, 1 Veterans Drive, Minneapolis, MN 55417, 612-725-2088
    National Toxicology Laboratories, Inc., 1100 California Ave., 
Bakersfield, CA 93304, 661-322-4250/800-350-3515
    One Source Toxicology Laboratory, Inc., 1213 Genoa-Red Bluff, 
Pasadena, TX 77504, 888-747-3774, (Formerly: University of Texas 
Medical Branch, Clinical Chemistry Division; UTMB Pathology-Toxicology 
Laboratory)
    Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA 
91311, 800-328-6942, (Formerly: Centinela Hospital Airport Toxicology 
Laboratory)
    Pathology Associates Medical Laboratories, 110 West Cliff Dr., 
Spokane, WA 99204, 509-755-8991/800-541-7891x7
    Phamatech, Inc., 10151 Barnes Canyon Road, San Diego, CA 92121, 
858-643-5555
    Quest Diagnostics Incorporated, 1777 Montreal Circle, Tucker, GA 
30084, 800-729-6432, (Formerly: SmithKline Beecham Clinical 
Laboratories; SmithKline Bio-Science Laboratories)
    Quest Diagnostics Incorporated, 400 Egypt Road, Norristown, PA 
19403, 610-631-4600/877-642-2216, (Formerly: SmithKline Beecham 
Clinical Laboratories; SmithKline Bio-Science Laboratories)

[[Page 7797]]

    Quest Diagnostics Incorporated, 8401 Fallbrook Ave., West Hills, CA 
91304, 818-737-6370, (Formerly: SmithKline Beecham Clinical 
Laboratories)
    Redwood Toxicology Laboratory, 3650 Westwind Blvd., Santa Rosa, CA 
95403, 707-570-4434
    South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South 
Bend, IN 46601, 574-234-4176 x1276
Southwest Laboratories, 4625 E. Cotton Center Boulevard, Suite 177, 
Phoenix, AZ 85040, 602-438-8507/800-279-0027
STERLING Reference Laboratories, 2617 East L Street, Tacoma, Washington 
98421, 800-442-0438
Toxicology & Drug Monitoring Laboratory, University of Missouri 
Hospital & Clinics, 301 Business Loop 70 West, Suite 208, Columbia, MO 
65203, 573-882-1273
U.S. Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson St., 
Fort George G. Meade, MD 20755-5235, 301-677-7085

*The Standards Council of Canada (SCC) voted to end its Laboratory 
Accreditation Program for Substance Abuse (LAPSA) effective May 12, 
1998. Laboratories certified through that program were accredited to 
conduct forensic urine drug testing as required by U.S. Department of 
Transportation (DOT) regulations. As of that date, the certification of 
those accredited Canadian laboratories will continue under DOT 
authority. The responsibility for conducting quarterly performance 
testing plus periodic on-site inspections of those LAPSA-accredited 
laboratories was transferred to the U.S. HHS, with the HHS' NLCP 
contractor continuing to have an active role in the performance testing 
and laboratory inspection processes. Other Canadian laboratories 
wishing to be considered for the NLCP may apply directly to the NLCP 
contractor just as U.S. laboratories do.

    Upon finding a Canadian laboratory to be qualified, HHS will 
recommend that DOT certify the laboratory (Federal Register, July 16, 
1996) as meeting the minimum standards of the Mandatory Guidelines 
published in the Federal Register on April 30, 2010 (75 FR 22809). 
After receiving DOT certification, the laboratory will be included in 
the monthly list of HHS-certified laboratories and participate in the 
NLCP certification maintenance program.

Janine Denis Cook,
Chemist, Division of Workplace Programs, Center for Substance Abuse 
Prevention, SAMHSA.
[FR Doc. 2013-02310 Filed 2-1-13; 8:45 am]
BILLING CODE 4160-20-P